PRASCEND is Proven and Effective

Get the most proven treatment available to control the clinical signs associated with pituitary pars intermedia dysfunction (PPID) in horses with PRASCEND.1 PRASCEND has not been evaluated in breeding, pregnant or lactating horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets.

Prascend product shot
DESCRIPTION & INDICATION
About PRASCEND

PRASCEND tablets are rectangular, light-red, half-scored tablets containing 1 mg pergolide, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only. It’s used for the control of clinical signs associated with PPID in horses. PRASCEND tablets should not be crushed due to the potential for increased human exposure. 

Learn More

How PRASCEND Works

Learn more about PRASCEND and how it works to help control clinical signs PPID in horses by watching this video. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. 

Conveniently Packaged
Dosage & Administration

Preserved and protected in foil blister packs, the single-scored tablets make it simple to adjust dosage. Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. PRASCEND tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets.

Read More About Dosing
3 Reasons to Choose PRASCEND1
FDA Approved Created with Sketch.
CONTROLLED SIGNS
Improved clinical signs within 3 months and continued through 6 months
Dosing Created with Sketch.
PROVEN SUCCESS
3 out of 4 horses evaluated were considered treatment successes
Easy Created with Sketch.
CLEAR IMPROVEMENT
Hypertrichosis (delayed shedding) improved in 89% of treated horses within 6 months
Save on PRASCEND

IMPORTANT SAFETY INFORMATION: PRASCEND is indicated for the control of clinical signs associated with pituitary pars intermedia dysfunction (equine Cushing's disease) in horses. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Humans should not ingest the product. Store this product separately away from human medicinal products to avoid accidental ingestion.

SAFETY & EFFICACY
FDA-Approved as Safe and Effective1,2

A large, multi-site field study showed PRASCEND was effective in controlling clinical signs associated with PPID in horses and ponies. Additional safety monitoring was conducted during the field study, as well as a six-month margin of safety study that demonstrated PRASCEND was safe for use in horses at the labeled dosage by performing studies that used 2X the maximum dosage.1,2 Treatment with PRASCEND may cause loss of appetite. Most cases are mild. 

EFFICACY
Field Study Evaluation1,2

The PRASCEND field study showed that 76% (86 of 113 horses) of evaluable cases were treatment successes. The horses showed these results within 180 days:

  • ACTH test results returned to normal or decreased by at least 50%
  • Dexamethasone suppression test (DST) returned to normal (<1 mcg cortisol per dL) on Day 180
  • Improvement in at least one clinical sign
  • No worsening in any clinical signs or development of new signs

PRASCEND is for use in horses only. PRASCEND has not been evaluated in breeding, pregnant or lactating horses.

PRASCEND TESTIMONIAL

Watch Spirit’s PPID Story

Horseowners Stacie and Tony Richmond describe the journey of their horse Spirit with PPID, and tell their story of managing his clinical signs of PPID with PRASCEND. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

IMPORTANT SAFETY INFORMATION: PRASCEND is for use in horses only. PRASCEND has not been evaluated in breeding, pregnant, or lactating horses. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changes also may be observed. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Not for use in humans. Do not ingest the product. PRASCEND tablets should not be crushed due to the potential for increased human exposure. Pergolide, like other ergot derivatives, may cause emesis, dizziness, lethargy or low blood pressure. Pregnant or lactating women should wear gloves when administering this product. Store this product separately away from human medicinal products and handle this product with care to avoid accidental ingestion. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Refer to the package insert for complete product information.